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Background: To assess acute effects of bevacizumab (anti-VEGF therapy) on cerebral microvessels and systemic
cardiovascular regulation.
Design and subjects: 20 consecutive patients with colorectal cancer (median age: 60.4 years, range 45.5-73.9 years)
received bevacizumab intravenously (5 mg/kg) uncoupled of chemotherapy. Prior to and within the first 24 hours
after bevacizumab infusion, patients were investigated for retinal endothelial function. A series of a triple 24-hour
ambulatory blood pressure measurement was conducted. Retinal endothelial function was determined as flicker
light-induced vasodilation. The integrity of baroreflex arc and autonomic cardiovascular control was examined by
stimulatory manoeuvres.
Results: Bevacizumab therapy significantly reduced the vasodilatory capacity of retinal arterioles in response to
flicker light. A slight decrease in diastolic pressure and heart rate was observed after bevacizumab infusion but this
was unrelated to changes in retinal function. The pressure response upon nitroglycerin was largely preserved after
bevacizumab infusion. The proportion of patients with abnormal nocturnal blood pressure regulation increased
under anti-angiogenic therapy. Autonomic blood pressure control was not affected by bevacizumab treatment.
Conclusions: Bevacizumab acutely impairs microvascular function independent of blood pressure changes.
Imaging of the retinal microcirculation seems a valuable tool for monitoring pharmacodynamic effects of
bevacizumab.
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Vascular endothelial growth factor (VEGF) is a key me-
diator of physiological and pathological angiogenesis. As
all solid tumors are dependent on pathological angiogen-
esis, anti-VEGF therapy has been approved in various
advanced and metastatic cancer types [1,2].
The rationale for treating cancer patients with angio-
genesis inhibitors has been on the assumption that un-
like in tumor vessels survival and functioning of the
normal vasculature is largely independent of VEGF
signalling [3]. Although clinical trials have proven the
clinical benefit of bevacizumab and other angiogenesis
inhibitors for the treatment of advanced cancers [1,2,4,5],
their use has been associated with hypertension and
thromboembolic events [5-8]. Several mechanisms of the
underlying cardiovascular toxicity have been proposed in-
cluding the inhibition of vasomotor effects by VEGF but
also structural and functional microvascular rarefaction
[9-11]. Accordingly, changes in endothelial function have
been observed in cancer patients treated by angiogenesis
inhibitors [10,11] and may serve as an important clinical
marker for cardiovascular complications and therapy out-
come. This hypothesis is corroborated by multiple clinical
trials showing an association between bevacizumab-
induced hypertension and response to therapy [12].
Here, we investigated the acute impact of bevacizumab
administration on retinal vessel reactivity in relation to
acute changes of cardiovascular regulation inclusive
blood pressure using the dynamic retinal vessel analysis
and evaluation of the autonomic nervous system. We
hypothesised that the dynamic retinal vessel analysis rep-
resents a useful non-invasive and easy applicable tool to
monitor functional microvascular alterations following
VEGF inhibition.
Materials and methods
Participants and ethics
Patients with histological confirmed metastatic or locally
advanced, inoperable colorectal cancer were enrolled
into the study. All patients had an indication for treat-
ment with bevacizumab / fluoropyrimidine containing
chemotherapy regimens and had not previously received
drugs directly targeting the VEGF pathway. Bevacizumab
was administered at a dose of 5 mg/kg one day before
the start of chemotherapy (day 0). To separate effects,
fluoropyrimidine based chemotherapy was started after
completion of all functional vascular measurements on
day 1 as described below. Patients were evaluated by dy-
namic retinal vessel analysis, autonomic function tests
and 24-hour ambulatory blood pressure monitoring
(ABPM) the day before (day −1) and the day after
bevacizumab infusion (day 1). ABPM was also applied
on the day of bevacizumab treatment (day 0). The proto-
col was approved by the Ethics Review Board of theMedical Faculty of the Dresden University of Technol-
ogy. All patients signed a written informed consent be-
fore inclusion into the study. The procedures conformed
to the principles of the Declaration of Helsinki (Clinical
Trials Registration NCT ID: NCT00740168)
Evaluation of the autonomic nervous system
All measurements were performed in a temperature and
humidity controlled specialized autonomic laboratory.
Consumption of caffeine or other xanthine containing
foods were not permitted on the examination day. Alcohol
and tobacco usage was ceased at the day preceding the
measurements. For continuous cardiovascular monitoring
using the SUEMPATHY device (Suess Medizin-Technik,
Aue, Germany) including the non-invasive blood pressure
monitoring CBM3000 device (Nihon Colin Co, Komaki,
Japan) the patient was placed in the supine position on a
tilt table [13]. After a resting period of 20 minutes the fol-
lowing manoeuvres were performed. First blood pressure
and heart rate responses to sublingual administration of
400 μg glyceroltrinitrate (Nitrolingual® akut Spray, Pohl
Boskamp, Hohenlockstedt, Germany) were recorded for
five minutes followed by deep metronomic breathing at a
rate of six breaths per minute for two minutes. For evalu-
ation of orthostatic reaction, patients were tilted to a 60°
upright position for 15 minutes. After 10 minutes of head-
up tilting, 400 μg glyceroltrinitrate was repeatedly admin-
istered while tilting was continued for another five
minutes. During head-up tilting the subsequent decrease
in ventricular filling and stroke volume evokes a transient
fall in arterial pressure which is counter-regulated by the
baroreflex arc with resultant tachycardia (vagal with-
drawal) and vasoconstriction (sympathetic activation).
This reaction is amplified by the application of vasodila-
tory agents such as glyceroltrinitrate. Orthostatic hypo-
tension may occur as a result of sympathetic dysfunction
which is defined as a reduction in systolic blood pressure
of at least 20 mmHg and/or diastolic pressure of at least
10 mmHg within three minutes of upright tilt [14].
Retinal vessel analysis
The Dynamic Retinal Vessel Analyzer (DVA, IMEDOS
GmbH, Jena, Germany) was used for digital fundus imaging
to perform static and dynamic retinal vessel analysis. Thirty
minutes after initiation of mydriasis of the right pupil using
1% tropicamide eye drops, each participant underwent
seven-field fundus photography using the system Visualis
(IMEDOS, FF450plus, 535–561 nm, 30° image, 1840×1360
pixel) as previously described [15]. The arteriolar-to-venular
ratio (AVR) was calculated from the central retinal arterial
and venous equivalents to quantify generalized arterial
narrowing. Dynamic vessel analysis was performed allowing
non-invasive diagnosis of microvascular function by meas-
uring the diameter of retinal arteries and veins continuously
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inal camera which interrupted the observation light with a
frequency of 12.5 Hz. The baseline diameter was measured
for 30 seconds in continuous light followed by three cycles
of 20-second flicker provocation and 50-second steady fun-
dus illumination. An arterial and venous segment of ap-
proximately 1.5 mm length was subsequently evaluated. An
interval of 30 seconds before each flicker stimulation was
considered as baseline to which the subsequent diameter
response was normalised. The peak dilation was the largest
vessel diameter at the end of each flicker stimulation
averaged across three flicker periods. Changes in ocular
hemodynamic parameters were expressed as percent
change over baseline values.
24-h Ambulatory blood pressure monitoring
Validated automated 24-hour blood pressure devices (Boso
GmbH, Jungingen, Germany) fulfilling the accuracy criteria
of the Association for the Advancement of Medical Instru-
mentation were used to measure blood pressure and heart
rate at intervals of 15 minutes at daytime (6–22 hours) and
of 30 minutes at night (22–6 hours) at three different occa-
sions. For each 24-hour measurement, blood pressures
were evaluated separately for daytime and nighttime
phases. Arterial daytime hypertension was diagnosed
according to the criteria of the European Society of Hyper-
tension (systolic blood pressure ≥ 140 mmHg and/or dia-
stolic blood pressure ≥ 90 mmHg). Nocturnal hypertension
was defined according to the guidelines of the American
Hypertension Association (systolic blood pressure >
120 mmHg and diastolic blood pressure > 75 mmHg). A
non-dipping blood pressure profile was existent when the
nocturnal blood pressure fall was less than 10% of daytime
values [18,19].
Multiple trigonometric regressive spectral analysis
Frequency analysis allows for quantification of cardiovas-
cular regulation by assessing spontaneous oscillations in
systemic arterial pressure and heart rate. Multiple trigono-
metric regressive spectral analysis (MTRS, ANS Consult,
Freital, Germany) was applied to corresponding values of
systolic blood pressure and of R-R interval derived from
electrocardiogram. A non-artifactual global data segment
of 2 min was analyzed. The local time window was set at
30 seconds and was shifted beat by beat for temporal de-
termination of frequency and amplitude [20,21]. Two
main spectral bands are usually considered: High fre-
quency (HF) oscillations (spectral band between 0.15 and
0.4 Hz) of heart rate relate to respiratory sinus arrhythmia
and, therefore, to parasympathetic cardiovagal tone. The
other oscillation of interest is in the low-frequency range
(spectral band between 0.04 and 0.15 Hz), usually centred
around 0.1 Hz (six cycles min-1). Low-frequency oscilla-
tions of heart rate (LF R-R) are thought to reflect thebaroreflex-mediated adjustments to the sinus node while
LF variations of systolic blood pressure are primarily the
result of sympathetically mediated fluctuations in periph-
eral vasomotor tone. The LF/HF ratio allows for quantifi-
cation of the relation between the two branches of the
autonomic nervous system. The total spectral power de-
scribes the amount of variability of a signal or stochastic
process at a specific frequency. Baroreflex sensitivity was
calculated as the slope of the linear regression line of co-
herent pairs of the detected oscillations of R-R interval
and systolic blood pressure (cross correlation coefficient >
0.7) [20,22,23]. The estimation of a global BRS index was
based on the weighted mean of all 300–500 individual
BRS values derived from all local data segments analysed
according to a variance ratio: (variance reduction of RRI/
variance reduction of SBP)2.
Statistical methods
The SPSS package version 17.0 (SPSS Inc., Chicago, IL,
USA) was used for all statistical computations. Data are
expressed as mean and standard deviation or quartiles.
Assuming non-Gaussian distribution, the acute effects of
bevacizumab treatment on hemodynamic parameters were
analyzed using Wilcoxon and Friedman Test. Spearman
correlation coefficients were calculated between changes
of continuous variables. Nominal data were compared by
Fisher’s exact test using cross-tabulation. The overall sur-
vival of patients was calculated by the methods of Kaplan-
Meier. Patients alive were censored at the day of last
contact. A two-tailed p-value of < 0.05 was used to indicate
significance.
Results
Twenty patients (15 men and 5 women) were enrolled into
the study. Eleven patients had rectal and nine colon cancer.
The median age was 60.4 [range 45.5-73.9] years. Overall
survival of all patients was 23.5 [15.0 – 31.8] months (me-
dian [95% CI]). Patients receiving bevacizumab as first line
treatment (n = 9) had an average survival of 27.1 [21.8 –
32.4] months and those receiving the antibody as second
line treatment (n = 11) survived on average 21.2 [14.0 –
28.5] months.
Retinal vessel analysis
Static retinal vessel analysis revealed that there was no ar-
teriolar narrowing based on age-normalised reference
values of the ARIC (Atherosclerosis Risk in Communities)
population. With bevacizumab, no change was observed
for arterial diameter, but there was a trend towards a
smaller venous diameter (day-1: 146 ± 22 μm vs. day+1:
143 ± 22 μm, p = 0.062, Figure 1a) resulting in a signifi-
cantly increased AVR after bevacizumab administration
(day-1: 0.89 ± 0.07 vs. day+1: 0.92 ± 0.06, p = 0.027,
Figure 1b). The arterial response to flicker provocation
Figure 1 a-d Functional and structural changes of retinal vessels in colorectal cancer patients in response to bevacizumab infusion.
While the diameter of retinal vessels were unaffected by bevacizumab treatment (Figure 1a) it evoked an increase in arteriolar-to-venular ratio
(Figure 1b) and a decrease in flicker-induced arterial vasodilation (Figure 1c). The reactivity of retinal arteries to flickering light tended to be lower
in patients with a pathological nocturnal blood pressure profile (non-dippers) than in those with physiological nocturnal blood pressure profile
(dippers) (Figure 1d). Legend: before (day-1) and after (day + 1) bevacizumab infusion.
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of VEGF inhibition while maximal venous dilation
remained unaffected (Figure 1c).24 h ABPM profile
The profiles of 24-h ABPM over three recording days are
depicted in Figures 2a and 2b. There was a significant re-
duction of diastolic pressure after bevacizumab adminis-
tration (Figure 2a). Twenty-four hour heart rate steadily
decreased over time (day −1: 80 ± 12 bpm; day 0: 76 ±
11 bpm; day +1: 74 ± 12 bpm; Friedman p = 0.047). All
other parameters were not affected by bevacizumab.
There was a trend towards a higher proportion of patients
with a hypertensive blood pressure profile under VEGF
inhibition (Figure 2c). The proportion of patients with
non-dipping blood pressure at night increased continu-
ously over the three recording days (Figure 2d). Although
not statistically significant, there was a trend towards a
lower retinal arterial reactivity in non-dippers versus
dippers irrespective of bevacizumab infusion (p > 0.05,
Figure 1d). Decrements of diastolic blood pressure from
day 0 to day +1 were neither associated with changes in
retinal vascular function (r = −0.250, p = 0.332) nor with
AVR (r = −0.422, p = 0.298).Autonomic testing
Sublingual nitroglycerin (Nitro) evoked similar de-
creases in systolic blood pressure before and after
bevacizumab infusion during supine (rest vs. nitro:
p = 0.001 at day-1, p = 0.001 at day+1) and upright position
(rest vs. +nitro: p = 0.001 at day-1, p = 0.002 at day+1)
(Figure 3a). The nitroglycerin-mediated fall in diastolic
blood pressure during head-up tilt (+nitro) was dimin-
ished after bevacizumab treatment (rest vs. +nitro,
p = 0.002 at day-1; p > 0.05 at day+1). Controlled breath-
ing at six cycles per min resulted in shifts from high to
low frequency oscillations of R-R interval (LF/HF ratio
of R-R interval: p = 0.010 at day −1; p = 0.006 at day+1)
which was not accompanied by adequate adjustments
in cardiovagal baroreflex sensitivity (Figure 3b) as ob-
served in healthy individuals [23]. Orthostatic challenge
induced significant increases in low frequency oscilla-
tions of R-R interval (p = 0.003 at day-1; p = 0.004 at
day+1) which were paralleled by an expected decrease
in baroreflex sensitivity (p = 0.001 at day-1; p = 0.003
at day+1). Cardiovagal outflow as indexed by high
frequency oscillations of R-R interval remained un-
changed during orthostasis. Bevacizumab treatment did
not modify autonomic adjustments of blood pressure
control during cardiovascular perturbation.
Figure 2 a-d 24-h ambulatory blood pressure profiles in colorectal cancer patients in response to bevacizumab infusion. Diastolic blood
pressure during daytime but not during nighttime decreased after bevacizumab infusion (Figure 2a,b). The proportion of individuals with
pathological blood pressure profile increased after bevacizumab (Figure 2c,d). Legend: systolic blood pressure (broken lines), diastolic blood
pressure (smooth lines); proportions are based on the diagnostic criteria of the European Society of Hypertension and the American
Hypertension Association before (day-1), during (day 0) and after (day+1) bevacizumab infusion.
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Many efforts have been made to target the VEGF path-
way in tackling cancer growth and tumor metastasis.
Anti-angiogenic therapies using anti-VEGF antibodies or
inhibitors of VEGF receptor 2 are increasingly employed
in combination with standard therapy for the treatment
of advanced cancer. However, predictive markers of effi-
cacy as well as of toxicity have not yet been established.
Imaging studies using diffusion contrast enhanced MRI
(DCE-MRI) have documented very early changes in re-
sponse to treatment with VEGF inhibitors [24,25]. How-
ever, DCE-MRI technique currently seems too complex
and expensive to be incorporated into large multicenter
trials [26].
Arterial hypertension is a candidate prognostic bio-
marker of response to VEGF therapy [27]. One hypoth-
esis is that VEGF inhibitors induce arterial hypertension
by increasing vasoconstriction through alteration of ni-
tric oxide (NO) bioavailability. Our method of dynamic
analysis of flicker-light induced vasodilation, originally
established for application in ophthalmological and car-
diovascular research, was therefore used to describe theacute impact of bevacizumab administration on non-
invasively measured retinal endothelial function in rela-
tion to blood pressure. We clearly demonstrate that
anti-angiogenic treatment of colorectal cancer acutely re-
duces flicker-light induced vasodilation of retinal arteries
independent of blood pressure changes. Furthermore,
blood pressure responses to a nitrovasodilator were not
altered by bevacizumab.
The vasodilatory response of retinal vessels to diffuse
luminance flicker stimulation is considered to be endo-
thelium dependent through release of NO [28]. Hence, a
diminished vasodilatory capacity in response to flicker-
light stimulation may indicate endothelial dysfunction.
In line with our results, endothelial dysfunction was also
reported by two other trials in cancer patients receiving
either bevacizumab or telatinib - a small molecule angio-
genesis inhibitor [10,11]. In these trials endothelial func-
tion was determined by laser Doppler fluxmetry using
pilocarpine [10] and flow-mediated vasodilation of the
brachial artery [11]. Although these methods measure
endothelial function in different vascular beds it seems
that the detrimental effect of angiogenesis inhibitors on
Figure 3 a-b Blood pressures and frequency bands of R-R interval during autonomic testing in response to bevacizumab infusion. The
blood pressure response to the vasodilator nitroglycerin was largely preserved except for diastolic blood pressure during passive standing
(Figure 3a). Cardiovascular perturbation by deep breathing and head-up tilt evoked a physiological shift from high to low frequency oscillations
in R-R interval which was unaffected by bevacizumab treatment (Figure 3b). Adequate adjustments of baroreflex sensitivity were only observed in
response to postural change but not to deep breathing irrespective of bevacizumab treatment. Legend: BP, blood pressure; BRS, baroreflex
sensitivity; DB6, deep breathing at six cycles per minute; HF, high frequency oscillations; LF, low frequency oscillations; Nitro, nitroglycerin; +Nitro,
Nitroglycerin application during head-up tilt before (smooth lines) and after (Broken lines) bevacizumab infusion.
Reimann et al. Experimental & Translational Stroke Medicine 2013, 5:7 Page 6 of 8
http://www.etsmjournal.com/content/5/1/7endothelial function is not confined to a certain vascular
bed and that arterial endothelial dysfunction is a general
phenomenon of pharmacological angiogenesis inhibition.
This is not surprising considering that VEGF receptor 2,
which confers the hypotensive actions of VEGF [29], is
virtually expressed by all endothelial cells.
It is however intriguing that we did not observe any
functional change in retinal veins after bevacizumab ad-
ministration. The lack of effect may be due to a marked
regional and segmental heterogeneity in vascular endo-
thelial function [30]. Accordingly, it has been reported
that shear stress elicits a smaller NO-dependent vaso-
dilation in veins and venules than in their arterial coun-
terparts even on the same segment [31]. Therefore, the
extent of possible changes in endothelium-dependentvasodilation induced by any stimulus may be inherently
less pronounced in the venous system. Furthermore, it is
not fully clear whether the endothelial NO-synthase is
also modulated by VEGF signaling in the venous circula-
tion and whether VEGF binding to its respective recep-
tors activates the same molecular machinery than in the
arterial system. Although VEGF receptors have been
identified on endothelial cells of veins a differential pat-
tern of signal transduction has been suggested along the
vascular tree [32].
Although elevated blood pressure or hypertension has
been the most frequently documented side effect of anti-
angiogenic treatment [33] we did not observe meaningful
changes in blood pressure nor in short-term blood pres-
sure regulation by anti-angiogenic therapy. The most
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quency of blood pressure elevation is a function of treat-
ment duration [34]. From a range of phase II clinical trials
the median interval to incident hypertension was esti-
mated at 4.5 - 6 months from initiation of bevacizumab
therapy [35,36]. Under the assumption that there is a pro-
gressive evolution of hypertension during chronic VEGF
inhibition our findings may imply that endothelial dys-
function is the first step in a sequence of deleterious
events evoked by VEGF blockade subsequently evolving
into clinical disease [10,11]. In vitro and in vivo studies
clearly demonstrated the role of VEGF in maintaining
baseline vascular tone by regulating NO synthesis and
prostacyclin release [37]. Loss of action by blockade of
VEGF signaling renders endothelial dysfunction highly
possible. Consistent with our above postulation, we ob-
served a higher frequency of an abnormal blood pressure
profile at night after bevacizumab administration. Further-
more, non-dipping status after anti-angiogenic therapy
tended to be related to a stronger impairment of micro-
vascular function. Although the latter data were not statis-
tically significant it still may support our hypothesis of a
central role of endothelial dysfunction in the development
of VEGF-induced hypertension.
We must acknowledge limitations of our pilot study.
The small number of patients precluded us from per-
forming multivariate modeling for analysis of possible
interactions, especially co-morbidities, nor from doing
correlation analysis of results of functional vascular ana-
lysis with outcome data of anti-angiogenic treatment.
However, it is important to note that the study design
allowed for separating the effect of anti-angiogenic treat-
ment from that of chemotherapy.
Conclusions
We demonstrate that the anti-VEGF antibody beva-
cizumab acutely impairs endothelial function of retinal
arteries irrespective of blood pressure changes. Hence,
functional imaging of the retinal microcirculation seems
a valuable tool to monitor early effects of anti-VEGF
treatment. Considering the close relationship between
therapeutic and side effects of VEGF blockade, flicker
provocation of retinal vessels may be a valid predictor of
therapy success and outcome.
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